Moxie Self-Management and Education Support Program

Официальное название

Moxie: A Self-management Education and Support Program Using Advertising Principles to Reduce Rehospitalization for Cardiovascular-related Illnesses

Обзор

Health education and self-management support are key facilitators of health behaviours. Moxie is a mixed media, self-management, education and support program for Albertans living with cardiovascular-related chronic conditions. Moxie is built upon our previous work within the ACCESS study (2015-21, n=4761), a RCT that previously tested the Moxie intervention in Alberta. Results demonstrated that MOXIE reduced the rate of hospitalizations (notably for hypertension, angina, hyper/hypoglycemia, heart failure decompensation, and acute kidney complications) by 34% in a population of low-income seniors living with cardiovascular-related chronic conditions. However, before Moxie can be effectively implemented province-wide, another trial is necessary to determine whether benefits can be observed in a larger cohort of patients with cardiovascular-related chronic conditions recruited immediately after hospital discharge (n=9000). Furthermore, the effectiveness of the two components of the ACCESS trial intervention will be assessed individually: (a) The Moxie Program, a tailored health and disease education component developed by a user-experience-centric design process incorporating patients, behavioural scientists, disease specialists, health system administrators and marketing/advertising professionals; and (b) the facilitated relay of clinical information to healthcare providers (letters). The trial is designed as a 2x2 factorial pragmatic, individual-level randomized pragmatic trial of these different interventions. This would yield the following groups: 1. Moxie SMES Program 2. Facilitated Relay 3. Moxie SMES Program and Facilitated Relay 4. True control Self-management education and support (SMES) intervention: This includes weekly physical mailers sent directly to patients' homes throughout the study containing information about chronic conditions, medication use, diet, physical activity, smoking cessation, and self-management/wellness principles. These messages will be refined by the social impact creative design partner and reviewed by clinicians and patients to ensure clinical safety and appropriate tone. Weekly mailers will encourage participants to enroll and consent to participate in the digital program by scanning a QR code or accessing a website where they will sign up for their own personalized Moxie mobile health app, complete a digital consent form and opt-in for electronic delivery of Moxie messages. Facilitated relay intervention: Participants allocated to this intervention will receive letters by mail, one addressed to them, one to their primary care provider, and one to their pharmacist. The letters will not be sent to their primary care provider directly; rather, they will be sent to patients who will be encouraged to take them to their primary care provider and pharmacist should they decide to do so. We hope this will empower patients to start discussions with their healthcare providers. This also supports patient autonomy by enabling patients to decide whether they want to take them to their provider or not. If for whatever reason they do not feel that this is going to be beneficial or of interest, they are not required to do so. The letter would contain a note to the patient's healthcare provider stating that their patient is at-risk of cardiovascular disease and that evidence has shown that the pharmacotherapy is effective in improving outcomes for patients similar to the participant. The primary outcome is readmission for cardiovascular-specific ambulatory care-sensitive conditions (ACSC) based on the most responsible diagnosis listed in CIHI Discharge Abstract Database-(DAD), using established algorithms within 12 months from randomization. This outcome includes all repeat admissions in the study period as recorded in the health record. This outcome is a count variable. We will calculate and compare each intervention arm's mean number and distribution of hospitalizations.

Вмешательства

• Поведенческое Moxie SMES Letters
  Weekly mailer for the Moxie SMES Program.
• Поведенческое Facilitated Relay Letter
  One-time Facilitated Relay letter for the participant to share with their healthcare provider.

Первичные конечные точки

• Hospital Readmissions [Срок оценки: Within 12 months from randomization.]

Вторичные конечные точки (6)

• Overall Mortality [Срок оценки: Within 12 months of randomization.]
• Cardiovascular-Kidney-Metabolic Death [Срок оценки: Within 12 months from randomization.]
• Cardioprotective Medication Initiation [Срок оценки: Within 12 months from randomization.]
• Medication Adherence [Срок оценки: Within 12 months from randomization.]
• Primary Care and Specialty Utilization [Срок оценки: Within 12 months from randomization.]
• Healthcare System Costs [Срок оценки: Within 12 months from randomization.]

Критерии участия

Критерии включения

Eligible participants will be adults aged 40-85 years who are being discharged to their home from general internal medicine or family medicine inpatient services (hospitalist) in one of 10 Alberta acute care facilities, whose admitting diagnosis was diabetes, coronary artery disease, heart failure, chronic kidney disease, or hypertension (see appendix for list of inclusion diagnoses).

Критерии исключения

Individuals who live at the same address/household as a person who is already in the study and/or those discharged from hospitals to continuing care facilities, rehabilitation facilities or another hospital will not be eligible to take part in the study. Individuals whose goals of care at the time of discharge from acute care were oriented towards comfort (i.e. C1 or C2 Goals of Care) will not be eligible to take part in the study. Individuals with markers indicating lack of competency/capacity in their inpatient ConnectCare record such as anything but full capacity on the medical record (i.e. "incapacitated" or "needs review"), or presence of an alternative decision maker, agent, or legal guardian listed on the medical record.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Факторный дизайн

Маскирование

Двойное слепое

Основная цель

Профилактика

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Публикации

• Campbell DJ, Tonelli M, Hemmelgarn B, Mitchell C, Tsuyuki R, Ivers N, Campbell T, Pannu R, Verkerke E, Klarenbach S, King-Shier K, Faris P, Exner D, Chaubey V, Manns B; Interdisciplinary Chronic Disease Collaboration. Assessing outcomes of enhanced chronic disease care through patient education and a value-based formulary study (ACCESS)-study protocol for a 2x2 factorial randomized trial. Implemen PMID 27671037
• "Statistics Canada Releases New Health of Canadians Report to Summarize the Current State of Health in the Country." Statistics Canadaa, 13 Sept. 2023, www.statcan.gc.ca/en/about/smr09/smr09_142. Accessed 13 Sept. 2023.
• "A Canadian Peer-reviewed Journal of Population Health and Health Services Research." Statistics Canada, www150.statcan.gc.ca/n1/pub/82-003-x/82-003-x2020010-eng.htm. Accessed 21 Oct. 2020.
• Sumithira, G., et al. "Incidence and prevalence of diabetes in patients with myocardial infarction: A study in a secondary care hospital." International Journal of Pharmaceutical Research (09752366) 12.3 (2020).
• Canadian Institute for Health Information. Hospital Morbidity Database (HMDB) metadata. Accessed October 28, 2024.
• Discharge abstract database metadata. Canadian Institute for Health Information. https://www.cihi.ca/en/dischargeabstract-database-dad-metadata. Published Unknown. Accessed October 17, 2023.
• "TCPS 2 (2018) - Chapter 3: The Consent Process." Panel on Research Ethics, ethics.gc.ca/eng/tcps2-eptc2_2018_chapter3-chapitre3.html#7b. Accessed 22 Jan. 2020.
• Ye C, Giangregorio L, Holbrook A, Pullenayegum E, Goldsmith CH, Thabane L. Data withdrawal in randomized controlled trials: Defining the problem and proposing solutions: a commentary. Contemp Clin Trials. 2011 May;32(3):318-22. doi: 10.1016/j.cct.2011.01.016. Epub 2011 Feb 4. PMID 21300179

Идентификаторы

NCT: NCT07280325 · Pro00141473

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗